# Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

> **NCT06784193** · PHASE1 · RECRUITING · sponsor: **Olema Pharmaceuticals, Inc.** · enrollment: 180 (estimated)

## Conditions studied

- Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)
- Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Metastatic Breast Cancer
- Fulvestrant
- Palazestrant

## Interventions

- **DRUG:** OP-3136
- **DRUG:** Fulvestrant
- **DRUG:** Palazestrant

## Key facts

- **NCT ID:** NCT06784193
- **Lead sponsor:** Olema Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-16
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06784193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06784193, "Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06784193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*